L3MBTL2
Lethal(3)malignant brain tumor-like protein 2
Protein Summary
Putative Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility. Its association with a chromatin-remodeling complex suggests that it may contribute to prevent expression of genes that trigger the cell into mitosis. Binds to monomethylated and dimethylated 'Lys-20' on histone H4. Binds histone H3 peptides that are monomethylated or dimethylated on 'Lys-4', 'Lys-9' or 'Lys-27'.
- ENST00000216237
- ENSP00000216237
- ENSG00000100395
- ENST00000452106
- ENSP00000414423
- L3MBT
- H-l(3)mbt-l
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor binding site profile | 0.71 | ||
histone modification site profile | 0.69 | ||
tissue sample | 0.68 | ||
transcription factor | 0.59 | ||
tissue | 0.56 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 14.79 (req: < 5)
Gene RIFs: 6 (req: <= 3)
Antibodies: 194 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 14.79 (req: >= 5)
Gene RIFs: 6 (req: > 3)
Antibodies: 194 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0